MRK dividend yield: 3.25%. VIG dividend yield: 1.29%. Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s. VIG tracks companies that have grown their dividends for 10+ consecutive years — the definition of dividend quality. With 315+ holdings and 0.06% expense ratio, it's a core holding for dividend growth investors. Lower current yield but superior long-term dividend growth versus high-yield alternatives.
Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.
VIG tracks companies that have grown their dividends for 10+ consecutive years — the definition of dividend quality. With 315+ holdings and 0.06% expense ratio, it's a core holding for dividend growth investors. Lower current yield but superior long-term dividend growth versus high-yield alternatives.
MRK currently offers a 3.25% yield (3.08/share/year) while VIG offers 1.29% (2.40/share/year). MRK provides higher current income. However, VIG has grown its dividend faster (9.2% 5Y CAGR), which may lead to better long-term income through compounding.
How much would $10,000 in MRK vs VIG earn per year?
With $10,000 invested today: MRK pays approximately $325/year. VIG pays approximately $129/year. With DRIP reinvestment over 10 years, these grow to $950/year (MRK) and $346/year (VIG).
Does MRK or VIG pay monthly dividends?
MRK pays quarterly dividends. VIG pays quarterly dividends. Neither pay monthly — both use a quarterly schedule, which is preferred by investors who need regular cash flow.
📬
Get this MRK vs VIG comparison by email
Save your analysis + get weekly dividend insights. Free forever.